查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1573229

化療嗜中性白血球低下症市場：按藥物類型、治療類型、給藥途徑和最終用途分類 - 2025-2030 年全球預測

Chemotherapy Induced Neutropenia Market by Type of Drug (Antibiotics, Antifungals, Antivirals), Treatment Type (Curative Therapy, Prophylactic Therapy), Route of Administration, End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年化療引起的嗜中性白血球低下症市值為73.9億美元，預計2024年將達到77.7億美元，複合年成長率為4.21%，到2030年預計將達到98.7億美元。

化療嗜中性白血球低下症（CIN）是化療引起的嗜中性白血球耗竭引起的一個重要的臨床問題。這些副作用需要仔細監測和管理，因為它們可能導致感染疾病、治療延誤和醫療費用增加。 CIN 管理的應用在腫瘤學中至關重要，主要使用顆粒細胞增生因子(G-CSF) 等生長因子、抗生素和支持性治療來降低感染風險並允許癌症治療方法。最終用途範圍包括醫院、癌症治療中心和促進 CIN 管理創新實踐的專科診所。

主要市場統計
基準年[2023] 73.9億美元
預測年份 [2024] 77.7億美元
預測年份 [2030] 98.7億美元
複合年成長率（%） 4.21%

CIN 管理市場由幾個關鍵因素驅動，包括癌症發生率上升、化療使用增加以及支持性護理治療的進步。最近的發展以及不斷擴大的意識計劃凸顯了生物相似藥、個人化醫療和以患者為中心的方法開發的潛在機會。此類創新不僅有望提供具有成本效益的替代藥物，而且還滿足了對治療範式的精確性日益成長的需求。然而，市場挑戰仍然存在，可能阻礙成長和可及性，包括藥物成本上漲、低收入地區獲得醫療保健的機會有限以及當前治療的潛在副作用。

為了利用這些機會，公司應該專注於新型生物相似藥和下一代 G-CSF 的研究，並整合資料分析和人工智慧來客製化干涉措施。透過專注於與醫療保健提供者的合作並投資於教育計劃，您可以提高市場佔有率和產品採用率。然而，為了實現永續成長，應對監管環境並保持價格競爭力非常重要。 CIN 管理市場競爭激烈且發展迅速，需要不斷創新並回應新興臨床需求和相關人員的需求。加強研發與臨床應用之間的橋樑對於尋求引領和轉變這一利基市場的市場相關人員至關重要。

市場動態：針對快速發展的化療引起的嗜中性白血球低下症市場揭示的關鍵市場見解

化療嗜中性白血球低下症市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 癌症盛行率上升導致化療的使用增加以及嗜中性白血球低下症症病例的相關增加
    • 提高對化療引起的嗜中性白血球低下症的認知，並透過早期診斷加強患者管理策略
    • 支持治療和生長因子的進展可有效降低嗜中性白血球低下症的風險
    • 政府和醫療保健部門努力加快化療引起的嗜中性白血球低下症減少症新治療方法的研發
  • 市場限制因素
    • 患者和醫療保健提供者缺乏對化療中嗜中性白血球低下症症風險和治療方案的認知和教育
    • 高昂的治療費用和有限的報銷選擇使患者無法接受化療嗜中性白血球低下症治療。
  • 市場機會
    • 將免疫療法和 g-CSF 結合起來治療化療引起的嗜中性白血球低下症的創新聯合治療
    • 使用基因篩檢來客製化化療嗜中性白血球低下症減少症治療的個人化醫療方法
    • 擴大遠端醫療服務，以遠端監測和管理接受化療的嗜中性白血球低下症患者
  • 市場挑戰
    • 影響化療嗜中性白血球低下症市場動態的經濟和醫療保健政策挑戰
    • 技術和基礎設施的限制阻礙了化療嗜中性白血球低下症治療的進展

波特五力：駕馭化療引起的嗜中性白血球低下症市場的策略工具

波特的五力框架是了解化療嗜中性白血球低下症市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解化療嗜中性白血球低下症市場的外部影響

外部宏觀環境因素在塑造化療嗜中性白血球低下症市場的績效動態方面發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解化療引起的嗜中性白血球低下症市場的競爭格局

對化療嗜中性白血球低下症市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位基質化療供應商的績效評估 -嗜中性白血球低下症市場

FPNV 定位矩陣是評估化療引起的嗜中性白血球低下症市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，規劃化療嗜中性白血球低下症市場的成功之路

對於希望加強在全球市場的影響力的公司來說，對化療嗜中性白血球低下症市場進行策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5.產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症發生率的增加增加了化療的使用，導致誘發嗜中性白血球低下症減少症的病例增加。
      • 提高對化療引起的嗜中性白血球低下症減少症的認知和早期診斷可增強患者管​​理策略
      • 支持治療和生長因子的進展可有效降低嗜中性白血球低下症的風險
      • 政府和醫療保健部門努力加快化療引起的嗜中性白血球低下症減少症新治療方法的研發
    • 抑制因素
      • 病人和醫護人員缺乏對化療中嗜中性白血球低下症症風險和治療選擇的認知和教育
      • 高昂的治療費用和有限的報銷選擇使患者無法接受化療引起的嗜中性白血球低下症的治療
    • 機會
      • 整合免疫療法和 G-CSF 的創新聯合治療，用於治療化療引起的嗜中性白血球低下症
      • 一種個人化醫療方法，利用基因檢測來客製化化療嗜中性白血球低下症的治療方法
      • 擴大遠端醫療服務，以遠端監測和管理接受化療的嗜中性白血球低下症患者
    • 任務
      • 影響化療嗜中性白血球低下症市場動態的經濟和醫療保健政策挑戰
      • 技術和基礎設施的限制阻礙了化療引起的嗜中性白血球低下症管理的進展
  • 市場區隔分析
  • 波特五力分析
  • PESTLE分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章化療引起的嗜中性白血球低下症的市場藥物（按類型）

  • 抗生素
  • 抗真菌藥物
  • 抗病毒藥物
  • 集落刺激因子
    • Filgrastim
    • 來格司亭
    • Pegfilgrastim

第7章化療引起的嗜中性白血球低下症市場治療（按類型）

  • 治療療法
  • 預防性治療

第8章化療嗜中性白血球低下症市場：依給藥途徑

  • 可注射的
  • 口服

第9章化療嗜中性白血球低下症市場：依最終用途分類

  • 醫院
  • 研究/學術機構
  • 專科診所

第10章美洲化療引起的嗜中性白血球低下症市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區化療引起的嗜中性白血球低下症市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲化療引起的嗜中性白血球低下症市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議
Product Code: MRR-1A1A064BFFBE

The Chemotherapy Induced Neutropenia Market was valued at USD 7.39 billion in 2023, expected to reach USD 7.77 billion in 2024, and is projected to grow at a CAGR of 4.21%, to USD 9.87 billion by 2030.

Chemotherapy Induced Neutropenia (CIN) is a significant clinical concern that occurs when chemotherapy reduces neutrophils, vital white blood cells critical for fighting infections. This adverse effect necessitates careful monitoring and management as it can lead to infections, treatment delays, and increased healthcare costs. The application of CIN management is essential in oncology, primarily focusing on the use of growth factors like granulocyte colony-stimulating factors (G-CSFs), antibiotics, and supportive care measures to reduce infection risks and enable continuance of cancer treatment regimens. The end-use scope encompasses hospitals, cancer treatment centers, and specialty clinics fostering innovative practices for managing CIN.

KEY MARKET STATISTICS
Base Year [2023] USD 7.39 billion
Estimated Year [2024] USD 7.77 billion
Forecast Year [2030] USD 9.87 billion
CAGR (%) 4.21%

The market for CIN management is driven by several key factors, including the rising prevalence of cancer, increasing chemotherapy usage, and advancements in supportive care treatments. Recent trends highlight the potential opportunities in the development of biosimilars, personalized medicine, and patient-centric approaches, alongside expanding awareness programs. Such innovations not only promise cost-effective alternatives but also cater to growing demands for precision in treatment paradigms. However, market challenges persist, including high drug costs, limited access to healthcare in low-income regions, and potential side effects of current treatments, which could hinder growth and accessibility.

To capitalize on these opportunities, companies should focus on research into novel biosimilars and next-generation G-CSFs, alongside integrating data analytics and AI to tailor interventions. Emphasizing collaborations with healthcare providers and investing in educational initiatives can enhance market presence and product adoption. However, navigating regulatory landscapes and maintaining price competitiveness are critical to attaining sustained growth. The nature of the CIN management market is highly competitive and rapidly evolving, necessitating continuous innovation and responsiveness to emerging clinical needs and stakeholder demands. Strengthening the bridge between R&D and clinical application will be imperative for market players aspiring to lead and transform this niche's landscape.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chemotherapy Induced Neutropenia Market

The Chemotherapy Induced Neutropenia Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer leading to higher chemotherapy usage and subsequent rise in cases of induced neutropenia
    • Growing awareness and early diagnosis of chemotherapy-induced neutropenia enhancing patient management strategies
    • Advancements in supportive care therapies and growth factors to effectively mitigate neutropenia risks
    • Government and healthcare initiatives promoting research and development of novel treatments for chemotherapy-induced neutropenia
  • Market Restraints
    • Lack of awareness and education among patients and healthcare providers regarding neutropenia risks and treatment options in chemotherapy
    • High treatment costs and limited reimbursement options hindering patient access to chemotherapy induced neutropenia therapies
  • Market Opportunities
    • Innovative combination therapies integrating immunotherapy and g-csf in chemotherapy induced neutropenia management
    • Personalized medicine approaches using genetic screening to tailor treatments for neutropenia caused by chemotherapy
    • Expansion of telehealth services for remote monitoring and management of neutropenic patients undergoing chemotherapy
  • Market Challenges
    • Economic and healthcare policy challenges impacting chemotherapy induced neutropenia market dynamics
    • Technological and infrastructure limitations hindering advancements in chemotherapy induced neutropenia management

Porter's Five Forces: A Strategic Tool for Navigating the Chemotherapy Induced Neutropenia Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chemotherapy Induced Neutropenia Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chemotherapy Induced Neutropenia Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chemotherapy Induced Neutropenia Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chemotherapy Induced Neutropenia Market

A detailed market share analysis in the Chemotherapy Induced Neutropenia Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chemotherapy Induced Neutropenia Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chemotherapy Induced Neutropenia Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chemotherapy Induced Neutropenia Market

A strategic analysis of the Chemotherapy Induced Neutropenia Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chemotherapy Induced Neutropenia Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., Apotex Inc., Baxter International Inc., BeyondSpring Pharmaceuticals, Biogen Inc., Coherus BioSciences, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, G1 Therapeutics, Hoffmann-La Roche Ltd., Kiadis Pharma, Mylan N.V., Novartis AG, OncoGenerix USA Inc., Pfizer Inc., Sandoz International GmbH, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Chemotherapy Induced Neutropenia Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type of Drug, market is studied across Antibiotics, Antifungals, Antivirals, and Colony Stimulating Factor. The Colony Stimulating Factor is further studied across Filgrastim, Lenograstim, and Pegfilgrastim.
  • Based on Treatment Type, market is studied across Curative Therapy and Prophylactic Therapy.
  • Based on Route of Administration, market is studied across Injectable and Oral.
  • Based on End-Use, market is studied across Hospitals, Research and Academic Institutes, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer leading to higher chemotherapy usage and subsequent rise in cases of induced neutropenia
      • 5.1.1.2. Growing awareness and early diagnosis of chemotherapy-induced neutropenia enhancing patient management strategies
      • 5.1.1.3. Advancements in supportive care therapies and growth factors to effectively mitigate neutropenia risks
      • 5.1.1.4. Government and healthcare initiatives promoting research and development of novel treatments for chemotherapy-induced neutropenia
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of awareness and education among patients and healthcare providers regarding neutropenia risks and treatment options in chemotherapy
      • 5.1.2.2. High treatment costs and limited reimbursement options hindering patient access to chemotherapy induced neutropenia therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovative combination therapies integrating immunotherapy and g-csf in chemotherapy induced neutropenia management
      • 5.1.3.2. Personalized medicine approaches using genetic screening to tailor treatments for neutropenia caused by chemotherapy
      • 5.1.3.3. Expansion of telehealth services for remote monitoring and management of neutropenic patients undergoing chemotherapy
    • 5.1.4. Challenges
      • 5.1.4.1. Economic and healthcare policy challenges impacting chemotherapy induced neutropenia market dynamics
      • 5.1.4.2. Technological and infrastructure limitations hindering advancements in chemotherapy induced neutropenia management
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chemotherapy Induced Neutropenia Market, by Type of Drug

  • 6.1. Introduction
  • 6.2. Antibiotics
  • 6.3. Antifungals
  • 6.4. Antivirals
  • 6.5. Colony Stimulating Factor
    • 6.5.1. Filgrastim
    • 6.5.2. Lenograstim
    • 6.5.3. Pegfilgrastim

7. Chemotherapy Induced Neutropenia Market, by Treatment Type

  • 7.1. Introduction
  • 7.2. Curative Therapy
  • 7.3. Prophylactic Therapy

8. Chemotherapy Induced Neutropenia Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
  • 8.3. Oral

9. Chemotherapy Induced Neutropenia Market, by End-Use

  • 9.1. Introduction
  • 9.2. Hospitals
  • 9.3. Research and Academic Institutes
  • 9.4. Specialty Clinics

10. Americas Chemotherapy Induced Neutropenia Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Chemotherapy Induced Neutropenia Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Chemotherapy Induced Neutropenia Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

LIST OF FIGURES

  • FIGURE 1. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET RESEARCH PROCESS
  • FIGURE 2. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET DYNAMICS
  • TABLE 7. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY FILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY LENOGRASTIM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PEGFILGRASTIM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY CURATIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY PROPHYLACTIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. JAPAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. MALAYSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. PHILIPPINES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. SINGAPORE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. SOUTH KOREA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. TAIWAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. THAILAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. VIETNAM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 130. DENMARK CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. EGYPT CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 140. FINLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 150. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. ISRAEL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 160. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 165. NETHERLANDS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 170. NIGERIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. NORWAY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 180. POLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 185. QATAR CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 190. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 195. SAUDI ARABIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 200. SOUTH AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 205. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 210. SWEDEN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 215. SWITZERLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 220. TURKEY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 225. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TYPE OF DRUG, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY COLONY STIMULATING FACTOR, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 235. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 236. CHEMOTHERAPY INDUCED NEUTROPENIA MARKET, FPNV POSITIONING MATRIX, 2023